Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Section 5 of 6

Economic information and modeling report

29 evidence topics · 13 sources

Modeling overview

Summary: absence of vonaprument economic evaluations and comparator cost-effectiveness evidence

No cost-effectiveness analysis, budget impact model, health technology assessment, or price of vonaprument (ANX007) was identified. ARCHER II, the phase 3 trial of monthly vonaprument 5.0 mg per eye versus sham in 659 participants, had a Data Monitoring Committee assessment of its Month 15 primary endpoint scheduled for the fourth quarter of 2026, so no product-specific efficacy input for a model was available. The manufacturer states that there is no assurance a product will be considered “cost-effective by third-party payors”. The comparator evidence consists of analyses of the two complement inhibitors approved in the United States, pegcetacoplan and avacincaptad pegol.

Two U.S. cost analyses based on 2022 Medicare reimbursement, estimated 2-year treatment costs of $70,000 (every month) and $34,600 (every other month) for pegcetacoplan, with modeled costs per QALY gained of $706,000 and $397,000, and 2-year costs of $67,400 (every month) and $40,600 (every other month) for avacincaptad pegol. For extrafoveal GA, the cost per mm2 of retinal pigment epithelium saved was higher with avacincaptad pegol than with pegcetacoplan for both dosing regimens ($119,000 vs $54,000 every month; $57,100 vs $31,400 every other month). A U.S. cost-utility model with authors from Apellis Pharmaceuticals, which included the costs and utility loss of informal caregiving, reported $77,735 per QALY gained over a lifetime horizon, and $55,806 per QALY gained for lesions at least 250 μm from the foveal center.

The Australian Pharmaceutical Benefits Advisory Committee (PBAC) assessed submissions for pegcetacoplan (November 2025) and avacincaptad pegol (March 2026). Each submission was a cost-utility analysis versus best supportive care with a 20-year time horizon; the pegcetacoplan model defined health states by ETDRS letter bands, and the avacincaptad pegol model by GA lesion size. For both products the PBAC stated that a price reduction would be required to achieve cost-effectiveness, and considered an ICER in the order of $55,000 to < $75,000 (pegcetacoplan) and $45,000 to < $55,000 (avacincaptad pegol) per QALY gained acceptable. For pegcetacoplan, the PBAC considered it reasonable to accept the financial estimates as the basis of a risk sharing arrangement. Should pegcetacoplan proceed to listing, the PBAC advised a cost-minimisation approach so that avacincaptad pegol was no more costly than pegcetacoplan. The NICE appraisal of pegcetacoplan was suspended after information the company provided in February 2025, which stated that it had not received MHRA marketing authorisation for the indication, and has since been discontinued.

Australian PBAC assessment of avacincaptad pegol: model structure, ICER, and cost-minimisation with pegcetacoplan

Budget impact model

Approach and framework

Budget impact model of vonaprument

No evidence found.

Perspective and time frame

Budget impact model of vonaprument: perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

Budget impact model of vonaprument: eligible population

No evidence found.

Cost assumptions

Price of vonaprument

No evidence found.

Medicare Part B payment limits for comparator complement inhibitors, October to December 2026
HCPCS code and productShort descriptionBilling unitPayment limit per billing unit (dollars)Notes
J2781 pegcetacoplan (Syfovre)“Inj, pegcetacoplan, 1mg”“1 MG”“135.267”“AMP-based payment limit”
J2782 avacincaptad pegol (Izervay)“Inj avacincaptad pegol 0.1mg”“0.1 MG”“100.563”Not reported
Medicare Part B spending and beneficiaries for comparator complement inhibitors, 2023 and 2024
HCPCS code and productTotal spending, 2023 (dollars)Total beneficiaries, 2023Total spending, 2024 (dollars)Total claims, 2024Total beneficiaries, 2024Average spending per claim, 2024 (dollars)Average spending per beneficiary, 2024 (dollars)
J2781 pegcetacoplan (Syfovre)“76651580.03”“17414”“403855394.8”“148576”“29338”“2718.173829”“13765.60757”
J2782 avacincaptad pegol (Izervay)Not reportedNot reported“190365232.8”“73172”“18308”“2601.613086”“10397.92619”
Medicare Part B quarterly spending and beneficiaries for comparator complement inhibitors, 2025 and first quarter of 2026
HCPCS code and productPeriodTotal spending (dollars)Total claimsTotal beneficiariesAverage spending per claim (dollars)Average spending per beneficiary (dollars)
J2781 pegcetacoplan (Syfovre)“2025 (Q1-Q4)”“451069360.05”“168366”“32021”“2679.1000561”“14086.673122”
J2781 pegcetacoplan (Syfovre)“2026 (Q1)”“109568082.68”“41654”“24179”“2630.4336361”“4531.5390496”
J2782 avacincaptad pegol (Izervay)“2025 (Q1-Q4)”“364934587.1”“140741”“27497”“2592.9515003”“13271.796454”
J2782 avacincaptad pegol (Izervay)“2026 (Q1)”“105232261.84”“41264”“23315”“2550.2196064”“4513.5004006”
Medicare payment for intravitreal injection (CPT 67028), 2025 and 2026
CPT code2025 non-facility total RVUs2026 non-facility total RVUs2025 non-facility pay (dollars)2026 non-facility pay (dollars)Change in non-facility pay, 2025 to 2026
“67028”“3.37”“3.42”“$109.01”“$114.23”“4.79%”

Model outcomes

Budget impact model of vonaprument: outcomes

No evidence found.

Results

Base case
Budget impact model of vonaprument: base case

No evidence found.

Scenario analyses
Budget impact model of vonaprument: scenario analyses

No evidence found.

Budget impact model discussion

Summary: inputs a vonaprument budget impact model would require

No budget impact model of vonaprument exists. A U.S. payer model would require four inputs that are not yet available: a price (none announced), efficacy and discontinuation data from ARCHER II, the labeled dosing frequency (ARCHER II tests monthly vonaprument 5.0 mg per eye), and the eligible population defined by an approved indication.

Comparator inputs exist for the two complement inhibitors already approved in the United States. October to December 2026 Medicare Part B payment limits were $135.267 per 1 mg of pegcetacoplan (J2781, an AMP-based payment limit) and $100.563 per 0.1 mg of avacincaptad pegol (J2782); launch list prices in 2023 were $2,190 and $2,100 per vial. Medicare Part B spending in 2025 was $451.1 million for Syfovre (32,021 beneficiaries; $2,679 per claim) and $364.9 million for Izervay (27,497 beneficiaries; $2,593 per claim), compared with $403.9 million (29,338 beneficiaries) and $190.4 million (18,308 beneficiaries) in 2024. The 2026 national non-facility Medicare payment for an intravitreal injection (CPT 67028) was $114.23. The manufacturer estimates that approximately 75,000 U.S. patients are actively treated with available therapies, about 10% of the 800,000 diagnosed with GA or under the care of retina specialists and about 5% of an estimated 1.5 million U.S. patients with GA.

The two Australian PBAC financial estimates illustrate the structure such a model would take: an epidemiological approach, a prevalence of 1.29% (pegcetacoplan, aged 60 years and older) or 0.52% (avacincaptad pegol, aged 50 years and older), the proportion with non-subfoveal GA (31.60% for avacincaptad pegol), an uptake curve, injections per year, and administration costs, over 6 years. Both estimates were sensitive to dosing frequency: the PBAC revised pegcetacoplan from 4.5 to 5.39 scripts per year, and for avacincaptad pegol the evaluation tested scenarios in which 50% or 100% of patients continued monthly dosing after year 1, after which the estimated year 6 cost was $70 million to < $80 million, compared with $60 million to < $70 million in the submission. The evaluation of avacincaptad pegol stated that market share calculations would be necessary if pegcetacoplan were listed, a consideration that would also apply to a third agent.